1
|
Kang H, Lee JB, Khatri I, Na Y, D’Souza C, Arruda A, Minden MD, Zhang L. Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib. Cancers (Basel) 2021; 13:cancers13205039. [PMID: 34680188 PMCID: PMC8533698 DOI: 10.3390/cancers13205039] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 10/01/2021] [Accepted: 10/06/2021] [Indexed: 11/16/2022] Open
Abstract
Simple Summary Persistence of infused cells is an important factor that dictates the outcome of adoptive cellular therapy (ACT). DNT therapy is a novel form of ACT with promising result in treating relapsed or refractory AML in preclinical and early clinical studies. However, in vivo kinetics of human DNTs in cancer-bearing host have not been previously investigated. This study was the first to investigate the persistence of DNTs and ways to improve it in patient-derived xenograft models. DNTs persistence was observed up to 50 days in various organs of leukemia-bearing hosts. However, the detected DNT level was low while significant level of persisting AMLs was observed. To improve the in vivo persistence and therapeutic efficacy of DNTs, we expanded DNTs in the presence of an PI3Kδ inhibitor, idelalisib (Ide). Ide treatment of healthy donor-derived DNTs promoted early memory subsets and improved overall fitness, reducing exhaustion while improving viability. These Ide-induced attributes led to prolonged persistence of DNTs, resulting in superior anti-leukemic activity in vivo. Further, Ide-treated DNTs improved the durability of the treatment response. Collectively, our study highlights the importance of DNT persistence and Ide-mediated improvements in the overall fitness of DNTs, which promote longer persistence in vivo and better treatment outcome. Abstract The double negative T cell (DNT) is a unique subset of T cells with potent anti-leukemic potential. Previously, DNT therapy has been shown to effectively target AML cells in patient-derived xenograft (PDX) models. Further, a recently completed phase I/IIa clinical study demonstrated the safety, feasibility, and potential efficacy in AML patients that relapsed after allogeneic hematopoietic stem cell transplantation. However, the persistence and durability of DNT-mediated anti-leukemic response is less well understood. In this study, we characterized the in vivo persistence of DNTs in PDX models. Further, we improved the efficacy and durability of DNT-mediated activity with phosphoinositide 3-kinase delta (PI3Kδ) inhibition. Mechanistically, DNTs treated with the PI3Kδ inhibitor, Idelalisib (Ide), exhibited early memory phenotype with superior viability and proliferative capacity but less cell exhaustion. Collectively, the findings from this study support the use of Ide-treated DNTs to improve its therapeutic outcome.
Collapse
Affiliation(s)
- Hyeonjeong Kang
- Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada; (H.K.); (J.B.L.); (I.K.); (Y.N.); (C.D.)
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada
| | - Jong Bok Lee
- Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada; (H.K.); (J.B.L.); (I.K.); (Y.N.); (C.D.)
| | - Ismat Khatri
- Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada; (H.K.); (J.B.L.); (I.K.); (Y.N.); (C.D.)
| | - Yoosu Na
- Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada; (H.K.); (J.B.L.); (I.K.); (Y.N.); (C.D.)
| | - Cheryl D’Souza
- Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada; (H.K.); (J.B.L.); (I.K.); (Y.N.); (C.D.)
| | - Andrea Arruda
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada; (A.A.); (M.D.M.)
| | - Mark D. Minden
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada; (A.A.); (M.D.M.)
| | - Li Zhang
- Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada; (H.K.); (J.B.L.); (I.K.); (Y.N.); (C.D.)
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada
- Correspondence: ; Tel.: +1-(416)-581-7521; Fax: +1-(416)-581-7515
| |
Collapse
|
2
|
Safina BS, Elliott RL, Forrest AK, Heald RA, Murray JM, Nonomiya J, Pang J, Salphati L, Seward EM, Staben ST, Ultsch M, Wei B, Yang W, Sutherlin DP. Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles. ACS Med Chem Lett 2017; 8:936-940. [PMID: 28947940 DOI: 10.1021/acsmedchemlett.7b00170] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Accepted: 08/25/2017] [Indexed: 11/30/2022] Open
Abstract
A novel selective benzoxazepin inhibitor of PI3Kδ has been discovered. Beginning from compound 3, an αPI3K inhibitor, we utilized structure-based drug design and computational analysis of dihedral torsion angles to optimize for PI3Kδ isoform potency and isoform selectivity. Further medicinal chemistry optimization of the series led to the identification of 24, a highly potent and selective inhibitor of PI3Kδ.
Collapse
Affiliation(s)
- Brian S. Safina
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Richard L. Elliott
- Discovery from Charles River, 8-9 Spire Green Centre, Harlow, Essex CM 19 5TR, United Kingdom
| | - Andrew K. Forrest
- Discovery from Charles River, 8-9 Spire Green Centre, Harlow, Essex CM 19 5TR, United Kingdom
| | - Robert A. Heald
- Discovery from Charles River, 8-9 Spire Green Centre, Harlow, Essex CM 19 5TR, United Kingdom
| | - Jeremy M. Murray
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jim Nonomiya
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jodie Pang
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Laurent Salphati
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Eileen M. Seward
- Discovery from Charles River, 8-9 Spire Green Centre, Harlow, Essex CM 19 5TR, United Kingdom
| | - Steven T. Staben
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Mark Ultsch
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Binqing Wei
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Wenqian Yang
- ChemPartner, 998 Halei Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai 201203, China
| | - Daniel P. Sutherlin
- Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|